Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy

Unspecified Adult Solid Tumor Clinical Trial

Official title:

Holographic Mm-wave Imaging in Radiation Oncology

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03789773
• Other study ID #: 0S-18-6
• Secondary ID: NCI-2018-029940S
• Status: Withdrawn
• Phase: N/A
• Start date: December 1, 2022
• Est. completion date: December 1, 2024

Study information

• Verified date: August 2022
• Source: University of Southern California
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial studies the quality of holographic mm-wave imaging in patients undergoing radiation therapy. Holographic mm-wave imaging is a common type of imaging used in airport body scanners that may be helpful in improving the efficiency and positioning of radiation oncology patients and their overall experience.

Description:

PRIMARY OBJECTIVES:

I. To obtain patient images in a clinical setting and assess their quality.

SECONDARY OBJECTIVES:

I. To assess the registration agreement through a voxel-voxel distance-to-agreement metric.

OUTLINE:

Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial computed tomography (CT) simulation.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 1, 2024
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who are scheduled to receive either an optical or CBCT imaging scan as part of their treatment management.

• The study will be open to English and Spanish speaking participants.

Exclusion Criteria:

• Patients that are not scheduled for fluoroscopic or optical imaging as part of the normal course of radiotherapy.

Related Conditions & MeSH terms

• Unspecified Adult Solid Tumor

Intervention

Device:
• Millimeter-Wave Holographic Imaging
Undergo mm-wave holographic imaging

Locations

Country	Name	City	State
United States	USC / Norris Comprehensive Cancer Center	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of Southern California	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Qualitative assessment of holographic image quality	Qualitative assessment of image quality by study physicians according to the scoring of each image as: 1 = High Quality (A); 2= Acceptable Quality (B); 3 = Poor/Unacceptable Quality (C). Lower value (1) represents a better score than higher value (3). There are no subscales and or total scores. The quality scores of the images will be tabulated.	Up to 1 year
Secondary	Image registration agreement between mm-wave holographic images and a cone-beam computed tomography (CBCT)/optical surface image	The distribution of the percent of points in voxel-voxel analysis to agree to better than 2 mm will be tabulated	Up to 1 year